Andere Sprachen Valerio Therapeutics London S.E.

Aktien

A0HMXA

FR0010095596

0NWK

Markt geschlossen - London S.E. Andere Börsenplätze 12:18:08 30.11.2020			% 5 Tage	% 1. Jan.
0,7551 ^EUR	-0,52 %		+514,40 %	+335,72 %

22.05.	Valerio Therapeutics S.A. gibt aktuelle Informationen zur klinischen Entwicklung der Phase 1/2-Studie mit VIO-01 bekannt	CI
30.04.	Valerio Therapeutics Société anonyme meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial	22.05.
Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	30.04.
Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	28.09.23
Biophytis' Finance Chief Resigns; Onxeo Exec Named Successor	02.05.23
Onxeo SA Reports Earnings Results for the Full Year Ended December 31, 2022	29.04.23
Onxeo SA Provides Update on the Development Program For Drug Candidate AsiDNATM	25.01.23
Onxeo SA Advances Its Second Lead Candidate Ox425 for the Treatment of Solid Tumors	30.11.22
Onxeo SA Reports Earnings Results for the Half Year Ended June 30, 2022	13.09.22
Onxeo SA Announces the Enrollment of the First Patient in the Phase 1B/2 Clinical Study Conducted by the European Itcc Consortium and Sponsored by Institut Curie	01.09.22
Onxeo Wins Bourse Approval To Delist From Denmark's Nasdaq First North Market	31.08.22
Onxeo Shareholders OK Delisting From Denmark's Nasdaq First North Market	18.08.22
Onxeo SA Announces U.S. Food and Drug Administration Clears Initial IND Drug Candidate AsiDNA	30.06.22
Onxeo S.A. Appoints Khalil Barrage as New Board Member	16.06.22
Onxeo S.A. Announces the Appointment of Dr. Shefali Agarwal as President	07.04.22
Onxeo S.A. Announces Executive Changes	07.04.22
Onxeo SA Reports Earnings Results for the Full Year Ended December 31, 2021	06.04.22
Onxeo SA to Present New Preclinical Data Highlighting Asidna’s Ability to Fight Tumor Resistance and Protect from Anticancer Treatment Toxicity At Aacr Annual Meeting 2022	31.03.22
Onxeo's DNA Repair Inhibitor Shows Potential in Treating Homologous Recombination Proficient Tumors	09.03.22
Onxeo’s New Preclinical Data Confirm the Relevance of Combining AsiDNA™ With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors	09.03.22
Onxeo S.A. Appoints Julien Miara as Interim CEO	03.01.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Valerio Therapeutics London S.E.

Aktien

A0HMXA

FR0010095596

0NWK

Andere Sprachen

Filter